Skip to main content

Apheresis Unit (Hematology)

Apherisis is a procedure that makes it possible to separate the various elements of the blood, in particular: 

  • the plasma (therapeutic plasmapherisis),
  • the red corpuscles (therapeutic erythropheresis),
  • the white corpuscles (therapeutic leucapheresis),
  • the hematopoietic stem cells (cytapheresis), essential for both analogous transplants (using cells taken from the patient) and allogenic transplants (using the cells of another donor). 

Apheresis is a technique of extraction by centrifugation in an extracorporeal blood circuit (CEC). The components not collected are reinjected into the donor. 

The Apheresis Unit at the Jules Bordet Institute receives, for the ULB-IRIS network as a whole, patients likely to benefit from the collection of stem cells. The Unit works in close cooperation with the various autotransplant centres for adults and with the Children's Hospital (HUDERF). 

We have been practicing apheresis in our service since 1970, with a nursing and technical staff trained especially for the purpose. Three doctors and four nurses are available and ensure the continuity of the medical care, in cooperation with the hematology service as a whole. The Unit has an emergency service that operates 24 hours a day. 

The extraction, handling and conservation of the hematopoietic stem cells is in accordance with good practices. Since 2009 we have been accredited under the inspection programme (JACIE, the "Joint Accreditation Committee of the ISCT and EBMT" ) which makes it possible to improve quality within the various teams involved in carrying out the hematopoietic transplants.  

The Apheresis Unit at the Jules Bordet Institute also gives our patients access to treatment using photopheresis. This treatment is indicated for Chronic Graft Versus Host Disease (CGVHD) that does not respond to the standard treatment and in certain cases of skin lymphomas. 


Research projects


Project 1

A Phase II study to assess the safety and the efficacy of extracorporeal photopheresis using the Theraflex ECP™ for patients with refractory chronic GVHD
  • Project Initiator : Philippe Lewalle
  • Collaboration(s) : Protocole de la société belge d’hématologie
  • Financing (or) support: Amis de l’Institut Bordet

Our team

Responsible Physician
Prof Philippe Lewalle - Hematologist

Dr Adriano Salaroli

Head Nurse
Patrick Crombez

Corine Mal
Walter Bellemans
Nicoletta Munteanu
Olivier Mugema

Aurélie Timmermans
Olivier Carabin​​​​​​​

Vanessa Vanpevenage

 Scientific publications

Mesenchymal stromal cells and natural killer cells: a complex story of love and hate.

Authors : Najar M, Fayyad-Kazan M, Merimi M, Burny A, Bron D, Fayyad-Kazan H, Meuleman N, Lagneaux L
Year : 2019
Journal : Curr Stem Cell Res Ther
Volume : 14(1)
Pages : 14-21

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Authors : Houot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F
Year : 2019
Journal : Leukemia
Volume : 33
Pages : 776-780

MiR302c, Sp1, and NFATc2 regulate interleukin-21 expression in human CD4+CD45RO+ T lymphocytes.

Authors : El-Said H, Fayyad-Kazan M, Aoun R, Borghol N, Skafi N, Rouas R, Vanhamme L, Mourtada M, Ezzeddine M, Burny A, Fayyad-Kazan H, Badran B
Year : 2019
Journal : J Cell Physiol
Volume : 234
Pages : 5998-6011

Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.

Authors : Quinten C, Kenis C, Decoster L, Debruyne PR, De Groof I, Focan C, Cornelis F, Verschaeve V, Bachmann C, Bron D, Luce S, Debugne G, Van den Bulck H, Goeminne JC, Baitar A, Geboers K, Petit B, Langenaeken C, Van Rijswijk R, Specenier P, Jerusalem G, Praet JP, Vandenborre K, Lycke M, Flamaing J, Milisen K, Lobelle JP, Wildiers H
Year : 2019
Journal : Qual Life Res
Volume : 28
Pages : 663-676

Sweet's syndrome induced by pegfilgrastim during a myelodysplastic syndrome AREB2: A case report.

Authors : Nelis S, Azerad MA, Drowart A, Lewalle P, Efira A
Year : 2019
Journal : Rev Med Interne
Volume : 40
Pages : 258-261

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more